Evidence map›Paper›PMID 36932871›Full record

Trial reportHead & neck2023

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.

Joshua D Smith, Megan L Ludwig, Apurva D Bhangale, Collin Brummel, Paul L Swiecicki, Francis P Worden, Steven B Chinn, Chaz L Stucken, Andrew J Rosko, Mark E P Prince and 12 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Head & neck, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. CD8JCO precision oncology · 2024
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Joshua D SmithDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0002-2076-7589
Megan L LudwigDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Apurva D BhangaleDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Collin BrummelDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Paul L SwiecickiDivision of Hematology & Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0003-2286-3555
Francis P WordenDivision of Hematology & Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Steven B ChinnDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Chaz L StuckenDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Andrew J RoskoDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Mark E P PrinceDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0002-1120-9008
Kelly M MalloyDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Keith A CasperDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Carol R BradfordDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Douglas B ChepehaDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0001-9062-3719
Jennifer ShahRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Caitlin A SchonewolfRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jonathon B McHughRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Mukesh K NyatiRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Avraham EisbruchRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Michelle L MierzwaRogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Matthew E SpectorDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0001-7646-6075
J Chad BrennerDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0003-3238-1111
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck CancerR01CA131290 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NYATI, MUKESH K. · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA131290NIDCD NIH HHS T32 DC005356NIH HHS P30-CA046592NIH HHS T32DC005356
6 · The paper itself

Abstract

backgroundWe sought to characterize early changes in CD8

methodsTumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8

resultsOne week after cetuximab, five patients (62.5%) had an increase in CD8

conclusionsWithin 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.

Indexed as

Oropharyngeal NeoplasmsCD8-Positive T-LymphocytesCetuximabHumansTumor MicroenvironmentCetuximabCD8cetuximabHPVoropharynxTILs

Identifiers

PMID36932871
PMCPMC13281285
OpenAlexW4327811465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.